Su Zhenzhen, Cai Bei, Wu Xiaojuan, Li Lixin, Wei Bin, Meng Liye, Wang Lu, Wang Lanlan
Department of Laboratory Medicine, West China Hospital of Sichuan University, Chengdu, China.
J Infect Dev Ctries. 2022 Jan 31;16(1):179-186. doi: 10.3855/jidc.15138.
Sodium taurocholate cotransporting polypeptide has been identified as the hepatitis B virus (HBV) entry receptor. However, information regarding the role of sodium taurocholate cotransporting polypeptide variants in the development of HBV-related advanced cirrhosis and hepatocellular carcinoma is limited.
Overall, 581 patients with chronic HBV infection were divided into the liver fibrosis or cirrhosis group based on the Fibrosis-4 index. Further, 183 patients with hepatocellular carcinoma were distributed into early/intermediate and advanced/end stage groups based on Barcelona Clinic Liver Cancer Staging approach. Three single nucleotide polymorphisms were genotyped by high resolution melting curve method. Serum biomarkers of liver function were detected, and hepatocellular carcinoma properties were collected as well.
Subjects with GA+AA genotypes at the rs4646287 polymorphism site were associated with a significantly higher rate of fibrosis development (rs4646287 GA+AA genotypes were 13.7% and 20.0% in the non-fibrosis and fibrosis group, respectively; p = 0.038). There were no significant differences between sodium taurocholate cotransporting polypeptide polymorphisms and hepatocellular carcinoma progression. The GA+AA genotype carriers of rs7154439 had relatively high albumin levels (p = 0.035). The rs2296651 GA genotype carriers tended to have solitary tumor nodule and without metastasis (p = 0.004 and 0.015, respectively).
Rs4646287 was associated with HBV-related fibrosis development. Sodium taurocholate cotransporting polypeptide polymorphisms were correlated with serum albumin level as well as hepatocellular carcinoma multifocality and metastasis. Therefore, integrating sodium taurocholate cotransporting polypeptide polymorphisms to a risk stratification algorithm may help clinicians manage the chronic HBV infection patients better.
牛磺胆酸钠共转运多肽已被确定为乙型肝炎病毒（HBV）的进入受体。然而，关于牛磺胆酸钠共转运多肽变体在HBV相关晚期肝硬化和肝细胞癌发生发展中的作用的信息有限。
总体而言，581例慢性HBV感染患者根据纤维化-4指数分为肝纤维化或肝硬化组。此外，183例肝细胞癌患者根据巴塞罗那临床肝癌分期方法分为早期/中期和晚期/终末期组。通过高分辨率熔解曲线法对三个单核苷酸多态性进行基因分型。检测肝功能的血清生物标志物，并收集肝细胞癌的相关特征。
rs4646287多态性位点具有GA+AA基因型的受试者与纤维化发展的发生率显著较高相关（rs4646287 GA+AA基因型在非纤维化组和纤维化组中分别为13.7%和20.0%；p = 0.038）。牛磺胆酸钠共转运多肽多态性与肝细胞癌进展之间无显著差异。rs7154439的GA+AA基因型携带者白蛋白水平相对较高（p = 0.035）。rs2296651 GA基因型携带者倾向于有孤立肿瘤结节且无转移（分别为p = 0.004和0.015）。
Rs4646287与HBV相关纤维化发展有关。牛磺胆酸钠共转运多肽多态性与血清白蛋白水平以及肝细胞癌的多灶性和转移相关。因此，将牛磺胆酸钠共转运多肽多态性纳入风险分层算法可能有助于临床医生更好地管理慢性HBV感染患者。
